Cellular Senescence and Iron Dyshomeostasis in Alzheimer’s Disease
AbstractIron dyshomeostasis is a feature of Alzheimer’s disease (AD). The impact of iron on AD is attributed to its interactions with the central proteins of AD pathology (amyloid precursor protein and tau) and/or through the iron-mediated generation of prooxidant molecules (e.g., hydroxyl radicals). However, the source of iron accumulation in pathologically relevant regions of the brain and its contribution to AD remains unclear. One likely contributor to iron accumulation is the age-associated increase in tissue-resident senescent cells that drive inflammation and contribute to various pathologies associated with advanced age. Iron accumulation predisposes ageing tissue to oxidative stress that can lead to cellular dysfunction and to iron-dependent cell death modalities (e.g., ferroptosis). Further, elevated brain iron is associated with the progression of AD and cognitive decline. Elevated brain iron presents a feature of AD that may be modified pharmacologically to mitigate the effects of age/senescence-associated iron dyshomeostasis and improve disease outcome. View Full-Text
Share & Cite This Article
Masaldan, S.; Belaidi, A.A.; Ayton, S.; Bush, A.I. Cellular Senescence and Iron Dyshomeostasis in Alzheimer’s Disease. Pharmaceuticals 2019, 12, 93.
Masaldan S, Belaidi AA, Ayton S, Bush AI. Cellular Senescence and Iron Dyshomeostasis in Alzheimer’s Disease. Pharmaceuticals. 2019; 12(2):93.Chicago/Turabian Style
Masaldan, Shashank; Belaidi, Abdel A.; Ayton, Scott; Bush, Ashley I. 2019. "Cellular Senescence and Iron Dyshomeostasis in Alzheimer’s Disease." Pharmaceuticals 12, no. 2: 93.
Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.